Clinical Trial Update: ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating ctDNA-guided de-escalation of adjuvant chemotherapy using dalpiciclib in HR-positive, HER2-negative breast cancer; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer | Phase 2 | Status: RECRUITING